View Older Stories View More Recent Stories

May 16, 2017 08:00AM Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the A
May 10, 2017 05:40PM Merck (MRK) Announces FDA Approval for KEYTRUDA as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic NSCLC
May 10, 2017 05:39PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespe
May 9, 2017 03:56PM Merck KGaA, Pfizer (PFE) Announce FDA Approval for BAVENCIO for Common Type of Advanced Bladder Cancer
May 9, 2017 03:53PM FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
May 5, 2017 07:05AM Merck (MRK) Announces EC Approval of KEYTRUDA for Patients with Relapsed/Refractory cHL
May 5, 2017 07:00AM European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or
May 3, 2017 08:00AM Merck to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 2, 2017 06:45AM Merck Announces First-Quarter 2017 Financial Results
Apr 25, 2017 08:00AM America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
Apr 24, 2017 05:40AM Merck (MRK) Reports New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 22, 2017 07:00AM Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 21, 2017 10:00AM Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chro
Apr 20, 2017 09:00AM Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Apr 19, 2017 08:06AM Merck (MRK) Announces 25 Data Presentations at ECCMID
Apr 19, 2017 08:00AM Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 10, 2017 04:30PM Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Apr 7, 2017 07:31AM Merck (MRK) Receives CRL from FDA for TECOS Study with Sitagliptin
Apr 7, 2017 07:30AM Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Apr 6, 2017 10:00AM Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Apr 5, 2017 06:53AM Merck (MRK) to Present New Data on ZEPATIER and Investigational Combination Therapy MK-3682B at Liver Congress
Apr 5, 2017 06:50AM Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congre
Apr 3, 2017 07:16AM Ziopharm Oncology (ZIOP), Merck (MRK) & Intrexon (XON) Announce Development Update on CAR-T Therapy for Cancer
Apr 3, 2017 06:45AM Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Mar 31, 2017 07:02AM Incyte (INCY), Merck (MRK) Provide Details on Pact to Investigate Epacadostat and KEYTRUDA
Mar 31, 2017 07:00AM Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Mar 24, 2017 08:14AM Merck (MRK) Announces EMA's CHMP Recommends Approval of KEYTRUDA to Treat Classical Hodgkin Lymphoma
Mar 24, 2017 08:13AM European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Mar 23, 2017 05:35PM Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 23, 2017 05:30PM FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 22, 2017 04:05PM Merck Animal Health Completes Acquisition of Vallée S.A.
Mar 14, 2017 05:07PM Merck (MRK) Announces FDA Approval for KEYTRUDA to Treat Patients with Refractory cHL or Relapses
Mar 14, 2017 05:05PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines o
Mar 14, 2017 04:45PM Merck (MRK) Provides Update on sBLA for KEYTRUDA in Previously Treated Advanced MSI-H
Mar 14, 2017 04:43PM Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 6, 2017 08:02AM Merck (MRK), Pfizer (PFE) Announce FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines
Mar 6, 2017 08:00AM Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Feb 28, 2017 01:47PM Merck Announces Second-Quarter 2017 Dividend
Feb 28, 2017 01:00PM Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Feb 26, 2017 12:30PM Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in
Feb 24, 2017 04:02PM Merck (MRK) Says V212 Reduced Incidence of Confirmed HZ Cases in First Phase 3 Trial
Feb 24, 2017 04:00PM In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromis
Feb 23, 2017 11:33AM Trump again vows to bring back U.S. jobs, but offers few details
Feb 20, 2017 08:00AM Aptus Health's RxStart(TM) Solution Launches with Electronic Health Record Partners to Engage Providers and Patients at the Point of Care
Feb 16, 2017 08:00AM Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Feb 14, 2017 05:03PM Merck (MRK) Stops EPOCH Study of Verubecestat in Mild to Moderate AD on Lack of Efficacy
Feb 14, 2017 05:00PM Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy
View More Recent Stories View Older Stories